Abacavir Sulfat

Abacavir Sulfate — Abacavir sulfate 300 mg tablet; antiretroviral nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination therapy for the treatment of HIV-1 infection. This entry augments the supplied product name with clinical context, handling, and safety features while preserving the original identification "Abacavir Sulfate" and the Size: 300mg.

Key specifications & dosing: Each tablet contains abacavir sulfate equivalent to 300 mg abacavir. Recommended adult dosing when used in combination therapy is 600 mg total daily (either 300 mg twice daily or 600 mg once daily), with pediatric dosing weight-based as per local guidance. Store at controlled room temperature; follow prescription labeling for full dosing adjustments. (medthority.com)

Mechanism & indication: Abacavir is a guanosine-analog NRTI that is metabolized intracellularly to carbovir-triphosphate, inhibiting HIV reverse transcriptase and reducing viral replication. It is indicated only in combination with other antiretroviral agents for the treatment of HIV-1 infection. (ncbi.nlm.nih.gov)

Safety & precautions: Serious, sometimes fatal hypersensitivity reactions have been reported; patients must be screened for the HLA-B*5701 allele before initiating therapy and abacavir must be permanently discontinued if hypersensitivity is suspected. Abacavir is contraindicated in known HLA-B*5701 positive patients and those with prior abacavir hypersensitivity. Clinicians should also be aware of reported signals and ongoing review related to cardiovascular risk (myocardial infarction) and other class warnings; prescribe according to official labeling and monitor patients appropriately. (fda.report)

Manufacturer & supply information: Supplied by EMDA; manufacturer/seller recorded as MOLEQULE-ON (New Zealand) for this listing. Originator/approved branded product historically marketed as Ziagen by ViiV Healthcare — generics and regional manufacturers may exist; confirm batch and regulatory documentation at the time of procurement. (hivprep.uw.edu)

Additional features & customer notes: Prescription-only product; ensure HLA-B*5701 screening, review hepatic function before use (contraindicated in moderate/severe hepatic impairment), counsel patients on signs of hypersensitivity, and advise not to stop therapy without medical advice. For full prescribing information, a local product leaflet and national regulatory label should be consulted. (fda.report)